glp 1 and potassium GLP-1 Agonist: The Good, the Bad the Ugly ๐งฌ Upcoming ACLM Webinar: "GLPโ1s:
Description
Albiglutide: The HARMONY Outcomes trial (2018) reported a 22% MACE reduction (HR 0.78, 95% CI 0.680.90) in 9463 T2DM patients, driven by reduced MI [18]
*FOR WHAT TO EXPECT ALONG THE WAY: Information provided does not cover all information relevant to the use of GLP-1 medications
Diabetes Technology & Therapeutics , 13(7), 735-742.
RWD provides the depth and breadth needed to address critical questions, revealing how GLP-1s perform across medical histories, comorbidities, label expansions, and populations not studied in clinical trials (such as pregnant women)
Cell Mol Biol
In terms of vomiting, 7 studies (with 381 and 329 subjects from the experimental and control groups, respectively) were included for analysis
